Released Nov 2, 2026, before the open
10-Q filed Nov 2, 2026, 33 days after period end · 0001193125-26-442634
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net Income | -$26.39M | -$22.54M |
| EPS Diluted | -$0.49 | -$9.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Seaport Therapeutics, Inc. · CIK 2042347 · Engraved from SEC EDGAR
ended Sep 30, 2026 · filed Nov 2, 2026 · 33 d after period end
+2.1% from the close of Oct 30, 2026 to the close of Nov 2, 2026, the first after the release.
Seaport Therapeutics reported third quarter 2026 results, with cash, cash equivalents, and investments of $403.8 million as of September 30, 2026.¶1¶2
R&D expenses were $23.9 million and G&A expenses were $6.5 million for the quarter ended September 30, 2026, and net loss was $26.4 million.¶3¶4¶5
Seaport announced positive topline data from a Phase 1 driving simulation trial of GlyphAllo and dosed the first patient in a Phase 2a trial of GlyphAgo in October.¶6¶7